Thus, we concluded that a combination of rosuvastatin and IM exerted growth-inhibitory effects against CML CD34+ cells but not against normal CD34+ cells. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.